Gubra | Sustainability Performance
Gubra A/S is involved in biotech research, focusing on drug discovery and development primarily related to obesity and metabolic diseases, with an emphasis on innovative therapeutic approaches.
2008
Denmark
201 - 500 employees
Biotechnology
$100M - 500M in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#3815
Overallⓘ#93
in Denmarkⓘ#67
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon certificatesDigital emissionsEnergy consumptionFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Controversy level
- Gubra's preclinical drug discovery services involve animal testing in obesity and metabolic disease research.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.